AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02444793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05082566
Description: Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
Study NCT02444793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
Study NCT01103466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atlas
Description: Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV
Study NCT01103466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenSura
Description: SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT04005287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WST-057 (4% pirenzepine) Lose Dose 2mL
Description: Topical Solution
Study NCT01103466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conform 2
Description: Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
Study NCT04030065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: 10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
Study NCT01374126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: Artesunate alone
Study NCT01374126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin + Artesunate
Description: Combination of azithromycin + artesunate
Study NCT00171301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
Study NCT04781101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: Conventional therapy sessions that were planned by a physiotherapist for the children were conducted by a physiotherapist experienced in paediatrics. The therapy sessions mainly focused on functions such as the regulation of muscle tone, correction of posture, elimination of stiffness, muscle strengthening, balance/coordination training and mobilisation (Figure 2). The sessions were planned to last 40 minutes.
Study NCT04781101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RoboGait®
Description: The RoboGait®-assisted gait system was used for the robot-assisted gait training. In addition to conventional therapy, 16 robot-assisted gait training sessions were conducted, each lasting 25 minutes for 2 days a week (400 minutes in total). Gait speed was 1.5 km/h in all sessions. Considering conditions such as joint limitations and spasticity, gait training was performed with patients bearing 45% to 75% of their weight.
Study NCT02637921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: 21 days confinement in normobaric hypoxic (FiO2 = 14%)
Study NCT02637921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia
Description: 21 days confinement in normobaric hypoxic (FiO2 = 14%)
Study NCT02637921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory
Description: Participants hava a standardized activity level throughout the intervention
Study NCT02637921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normoxia
Description: 21 days confinement in normobaric normoxic (FiO2 = 21%) environment
Study NCT02637921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed Rest
Description: Participants remain on supine bed rest throughout the intervention
Study NCT02637921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed Rest
Description: Participants remain on supine bed rest throughout the intervention
Study NCT02637921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardised nutritional intake
Description: Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
Study NCT00002798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Study NCT00002798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT02637921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardised nutritional intake
Description: Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
Study NCT03816566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patch
Description: A standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject. The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy.
Study NCT02181426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac Dose
Description: Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
Study NCT02181426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Dose
Description: Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
Study NCT04329897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Software Messaging
Description: Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
Study NCT01225432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: 12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
Study NCT03274024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Implant
Description: Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube
Study NCT03274024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with Mitomycin C
Description: Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure
Study NCT02837445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PHC ON
Description: Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
Study NCT02837445 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PHC OFF
Description: Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
Study NCT00119106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Antiretroviral
Study NCT00119106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00730132 — intervention group
Intervention type: DRUG
Intervention: Ezetimibe
Description: Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
Study NCT00730132 — intervention group
Intervention type: DRUG
Intervention: Statin
Description: Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
Study NCT01626391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237
Description: TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
Study NCT01626391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
Study NCT01815216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Gastric bypass surgery
Study NCT01815216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain activity in resting state
Description: Measure of activity in brain networks during resting state
Study NCT01815216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain activity in resting state
Description: Measure of activity in brain networks during resting state
Study NCT00443703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0518 (raltegravir)
Description: MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
Study NCT00443703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: KALETRA™ (lopinavir (+) ritonavir )
Description: KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
Study NCT00443703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo
Description: MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
Study NCT00443703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
Study NCT01815216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory performance
Description: Assess concentration in 2D-location task (i.e. memory game)
Study NCT01815216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory performance
Description: Assess concentration in 2D-location task (i.e. memory game)
Study NCT00868985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350 plus electrolytes
Description: Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
Study NCT00868985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350 without electrolytes
Description: Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
Study NCT01742533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy
Study NCT00587301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lap-Band
Description: Obesity and adolescents
Study NCT02349243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Description: 200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
Study NCT02349243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
Study NCT02866045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided fine needle biopsy
Description: EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
Study NCT02866045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single incision needle knife biopsy
Description: For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
Study NCT02589483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The rectal anastomosis will be reinforced with HemoPatch.
Description: Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
Study NCT02589483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: The rectal anastomosis reinforced with Hemopatch
Study NCT01440673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant 80 mg, Aprepitant 125 mg
Study NCT02573233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02573233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893/REGN668
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02573233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate and salmeterol
Description: Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
Study NCT02573233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone propionate and salmeterol
Description: Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
Study NCT02573233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide and formoterol
Description: Pharmaceutical form:inhalation aerosol Route of administration: inhaled
Study NCT02573233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: budesonide and formoterol
Description: Pharmaceutical form:inhalation aerosol Route of administration: inhaled
Study NCT02573233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate and formoterol
Description: Pharmaceutical form:inhalation aerosol Route of administration: inhaled
Study NCT02573233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mometasone furoate and formoterol
Description: Pharmaceutical form:inhalation aerosol Route of administration: inhaled
Study NCT03724617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells combined with collagen scaffold
Description: 3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.
Study NCT00925691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RV lead
Description: The RV lead is implanted at the apex or at the interventricular septum
Study NCT00925691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV lead
Description: The RV lead is implanted at the apex or at the interventricular septum
Study NCT03850418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated
Study NCT00563368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: phentermine 15 mg and topiramate 92 mg, po once daily
Study NCT00563368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: phentermine 7.5 mg and topiramate 46 mg, po once daily
Study NCT00563368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: topiramate 46 mg, po once daily
Study NCT00563368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: topiramate 92 mg, po once daily
Study NCT00563368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phentermine
Description: phentermine 7.5 mg, po once daily
Study NCT00563368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phentermine
Description: phentermine 15 mg, po once daily
Study NCT00563368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VI-0521
Description: placebo, po once daily
Study NCT04369768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: restoration of permanent molars affected with MIH
Description: restore MIH affected molars using direct composite or preformed metal crowns
Study NCT03838367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg leronlimab
Description: leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Study NCT03838367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 525 mg leronlimab
Description: leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Study NCT03838367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 mg leronlimab
Description: leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Study NCT03838367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUC 5 Carboplatin
Description: Carboplatin is an anticancer drug chemotherapy drug.
Study NCT03259243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
Study NCT03259243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
Study NCT03053557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Coach
Description: Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
Study NCT01596855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: TIW dosing, capsule
Study NCT01596855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: TIW
Study NCT03091790 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Mesh
Description: Synthetic mesh used during open ventral hernia repair
Study NCT03091790 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biologic Mesh
Description: Biologic mesh used during open ventral hernia repair
Study NCT03170570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
Study NCT01869634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir with ritonavir and fixed-dose viread+emtricitabine daily
Study NCT05140772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptiven
Description: IV administration daily for 7 days